Goldman Sachs Group set a €95.00 ($110.47) target price on Merck KGaA (FRA:MRK) in a research note released on Wednesday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.
MRK has been the subject of several other research reports. Warburg Research set a €100.00 ($116.28) price target on Merck KGaA and gave the stock a neutral rating in a research note on Wednesday, September 12th. Credit Suisse Group set a €93.00 ($108.14) price target on Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, October 23rd. Commerzbank set a €100.00 ($116.28) price target on Merck KGaA and gave the stock a buy rating in a research note on Thursday, November 8th. Nord/LB set a €82.00 ($95.35) price target on Merck KGaA and gave the stock a neutral rating in a research note on Thursday, August 9th. Finally, Sanford C. Bernstein set a €105.00 ($122.09) price target on Merck KGaA and gave the stock a buy rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of €98.00 ($113.95).
MRK stock traded up €2.00 ($2.33) during mid-day trading on Wednesday, hitting €95.50 ($111.05). 1,113,570 shares of the stock were exchanged. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.